Cell Medica Acquires Catapult Therapy for Lead WT1-TCR T-Cell Therapy – Genetic Engineering & Biotechnology News (blog)
BioPharma-Reporter.com |
Cell Medica Acquires Catapult Therapy for Lead WT1-TCR T–Cell Therapy
Genetic Engineering & Biotechnology News (blog) Cell Medica is exploiting its proprietary activated T cell, chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) platforms to develop cellular immotherapies targeting cancer. Lead product CMD-003 (baltaleucel-T) is being evaluated in … Cell and Gene Therapy Catapult Announces Cell Medica Acquisition of WT1 T–cell TherapyPR Newswire UK (press release) Cell Medica Acquires WT1 Cancer Immunotherapy from Cell and Gene Therapy CatapultBusiness Wire (press release) |
Fast Company |
The Ethics Of CRISPR
Fast Company “The worst thing that could happen would be for [CRISPR] technology to be speeding ahead in laboratories,” Doudna tells Fast Company. “Meanwhile, people are unaware of the impact that’s coming down the road.” That’s why Doudna and her colleagues … Scientists Used CRISPR to Reverse Huntington’s Disease in MiceGizmodo CRISPR Pioneer Doudna: Humans on Cusp of ‘New Age in … – KQEDKQED Firefly Gene Illuminates Ability of Optimized CRISPR-Cpf1 to …Bioscience Technology |
|
GE and the Mayo Clinic back software to bring cancer-fighting gene therapies to market
TechCrunch Behind the incredible process of developing targeted gene therapies to fight diseases like cancer lies an incredibly mundane problem that prevents these treatments from getting to patients — paperwork and procedures. While $5.7 billion was invested in … GE Ventures, Mayo Clinic Ventures and DFJ Invest $13.75M in First Software Platform to Accelerate Cancer Cure …GlobeNewswire (press release) |
TechCrunch |
GE and the Mayo Clinic back software to bring cancer-fighting gene therapies to market
TechCrunch Behind the incredible process of developing targeted gene therapies to fight diseases like cancer lies an incredibly mundane problem that prevents these treatments from getting to patients — paperwork and procedures. While $5.7 billion was invested in … GE Ventures, Mayo Clinic Ventures and DFJ Invest $13.75M in First Software Platform to Accelerate Cancer Cure …GlobeNewswire (press release) |
Washington Post |
He broke ground in stem–cell research. Now he’s running for Congress.
Washington Post The small pack of scientists running for political office has grown by one. Stem–cell researcher Hans Keirstead, 50, announced last week that he will try to unseat California’s Rep. Dana Rohrabacher (R). Keirstead, a Democrat with a PhD in neuroscience … |